Core Viewpoint - A securities class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO registration statement, impacting investors who purchased shares during the IPO [1][7]. Allegations Against Lineage, Inc. - The lawsuit claims that Lineage's Registration Statement for its IPO, effective on July 24, 2024, contained significant misrepresentations regarding the company's business state and industry trends [7]. - It is alleged that Lineage falsely claimed that COVID-19 had accelerated growth in cold storage demand, which would benefit the company in the long term [7]. - The company reportedly concealed ongoing business challenges, including: - Customers destocking inventory that was built during the pandemic [7]. - A market-wide shift towards maintaining leaner inventories [7]. - Increased overall cold storage supply affecting occupancy rates and pricing power, particularly due to unsustainable price hikes imposed by Lineage [7]. Impact on Investors - Investors have a legal deadline until September 30, 2025, to seek appointment as lead plaintiff in the case [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Fiserv To Contact Him Directly To Discuss Their Options The market began to learn the truth about Defendants' fraud on April 24, 2025. On that date, Fiserv shocked investors by reporting Clover GPV growth of only 8 percent for the first quarter of 2025, a material stepdown from 2024 GPV rates of between 14 and 17 percent. The Company attributed this slowing growth to lower 202 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lockheed Martin To Contact Him Directly To Discuss Their Options As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose (1) that Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reportin ...

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for allegedly making false statements regarding its oil production activities, leading to investor damages during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit was filed on behalf of purchasers of Sable Offshore Corp. securities between May 19, 2025, and June 3, 2025, and/or related to the company's secondary public offering on May 21, 2025 [1]. - Defendants allegedly misrepresented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not, resulting in materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors in this case [4]. - The firm encourages affected investors to contact them for assistance and to join the lawsuit [5].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious health risk in premature infants [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Reckitt securities between January 13, 2021, and July 28, 2024 [1]. - Investors have until August 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Reckitt failed to adequately warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants consuming its formula [3][4]. Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt made misleading statements and omissions regarding its business, financial condition, and prospects during the class period [4]. - Specific allegations include failing to disclose the risks associated with Enfamil, the potential impact on sales, and the exposure to legal claims [4]. - As a result of these omissions, Reckitt's positive statements about its business were deemed materially false and misleading [4]. Group 3: Company Background - Reckitt is a UK-based global consumer goods company facing over 500 product liability lawsuits related to its infant formula [3]. - The lawsuits claim that Reckitt and its competitor Abbott Laboratories did not adequately warn about the risks associated with their cow milk-based formulas [3]. Group 4: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected individuals to reach out for more information [1][5]. - The firm specializes in representing individual and institutional investors in complex litigation [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $50,000 in Alto to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Alto, with a deadline of September 19, 2025, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Alto and its executives made false statements regarding ALTO-100's effectiveness and overstated the company's business and financial prospects [6]. Group 2: Stock Performance and Market Reaction - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [7]. - Following the announcement, analysts, including Jeffries, reduced their price target for Alto from $33 to $17, expressing concerns about the company's biomarker approach to CNS disorders and psychiatry [8].

Core Insights - Fiserv, Inc. has revised its 2025 outlook for refined organic revenue growth from a previous range of 10-12% to a flat 10% due to delays in company launches and initiatives [2] - Following the announcement of the revised guidance, Fiserv's stock price experienced a significant decline of over 17%, opening at $137.00 per share on July 23, 2025 [3] Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Fiserv on behalf of stockholders, focusing on possible violations of federal securities laws and other unlawful business practices [1] - The law firm encourages investors who have suffered losses to contact them for discussions regarding their legal rights [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Flywire To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Flywire between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 30, 2025 (GLO ...

Core Insights - The J.M. Smucker Company is under investigation for potential violations of federal securities laws and unlawful business practices [1][3] Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3] - For Q3 2025, Smucker reported a comparable net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3] - In Q4 2025, Smucker experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, incurring an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [4] - Following the disappointing Q4 results, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [4] Strategic Outlook - The company updated its 2026 financial plan to reflect decreased net sales in the Sweet Baked Snacks segment, indicating sustained underperformance since the acquisition of Hostess Brands [4]

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims against P3 Health Partners, Inc. regarding potential violations of federal securities laws due to misleading statements made by the company and its executives [1][2]. Summary by Relevant Sections Allegations and Investigation Focus - The investigation aims to determine if P3 Health Partners and its officers made false or misleading statements that violated federal securities laws [1]. Triggering Events - On November 12, 2024, P3 reported disappointing financial results, including a negative adjusted EBITDA of $15 million due to a write-down of midyear risk adjustment receivables, and an additional $10 million in expenses from negative medical claims developments. The company also incurred another $10 million in network and operating expenses. As a result, the stock price plummeted from $19.50 to $10.45, marking a decline of 46.4% within two days [2][5]. - On March 28, 2025, P3 disclosed in its annual Form 10-K that it received a civil investigative demand from the Department of Justice regarding its marketing practices and remuneration for Medicare Advantage brokers and related parties [5].